NASDAQ:RTRX - Travere Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.00
  • Forecasted Upside: 2.19 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$27.40
▼ -1.79 (-6.13%)
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RTRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RTRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$28.00
▲ +2.19% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $28.00, with a high forecast of $33.00 and a low forecast of $21.00. The average price target represents a 2.19% upside from the last price of $27.40.
Buy
The current consensus among 6 investment analysts is to buy stock in Travere Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $33.00High
i
9/17/2020WedbushInitiated CoverageOutperform$33.00High
i
Rating by L. Chico at Wedbush
8/24/2020Bank of AmericaInitiated CoverageBuy$30.00Low
i
7/31/2020BarclaysReiterated RatingHold$21.00Medium
i
7/13/2020BMO Capital MarketsLower Price Target$34.00 ➝ $31.00Medium
i
6/16/2020BTIG ResearchInitiated CoverageBuy$25.00Low
i
5/19/2020Canaccord GenuityReiterated RatingBuy$26.00High
i
5/12/2020BMO Capital MarketsBoost Price TargetOutperform$33.00 ➝ $34.00High
i
2/25/2020BarclaysDowngradeOverweight ➝ Equal Weight$19.00High
i
8/23/2019Jefferies Financial GroupSet Price TargetBuy$33.00N/A
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/23/2019William BlairReiterated RatingBuyHigh
i
Rating by T. Lugo at William Blair
8/23/2019Canaccord GenuityLower Price TargetBuy$38.00 ➝ $23.00Medium
i
Rating by Michelle Gilson at Canaccord Genuity
8/23/2019BMO Capital MarketsLower Price TargetPositive ➝ Outperform$38.00 ➝ $33.00Medium
i
8/23/2019Nomura SecuritiesLower Price TargetBuy$57.00 ➝ $33.00Medium
i
8/23/2019BarclaysLower Price TargetOverweight$36.00 ➝ $20.00High
i
8/22/2019BMO Capital MarketsSet Price TargetBuy$38.00Low
i
Rating by Do Kim at BMO Capital Markets
8/22/2019JMP SecuritiesSet Price TargetBuy$32.00 ➝ $26.00Low
i
8/8/2019Nomura SecuritiesReiterated RatingBuy$57.00Medium
i
8/7/2019Canaccord GenuitySet Price TargetBuy$38.00Low
i
Rating by Michelle Gilson at Canaccord Genuity
7/5/2019William BlairReiterated RatingBuyMedium
i
Rating by T. Lugo at William Blair
7/1/2019Canaccord GenuityBoost Price TargetBuy$37.00 ➝ $41.00High
i
4/22/2019BarclaysInitiated CoverageOverweight ➝ Overweight$36.00Medium
i
4/17/2019William BlairReiterated RatingOutperformLow
i
Rating by T. Lugo at William Blair
2/26/2019SVB LeerinkReiterated RatingOutperformLow
i
Rating by J. Schwartz at SVB Leerink LLC
11/19/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$57.00High
i
10/30/2018Jefferies Financial GroupInitiated CoverageBuy$44.00High
i
8/17/2018Canaccord GenuityInitiated CoverageBuyHigh
i
4/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$44.00 ➝ $43.00High
i
10/6/2017BMO Capital MarketsReiterated RatingBuy$44.00N/A
i
4/6/2017William BlairReiterated RatingOutperformMedium
i
Rating by T. Lugo at William Blair
3/2/2017BMO Capital MarketsLower Price TargetOutperform$46.00 ➝ $45.00N/A
i
Rating by Do Kim at BMO Capital Markets
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/A
i
Rating by Liisa Bayko at JMP Securities
12/14/2016BMO Capital MarketsSet Price TargetBuy$46.00N/A
i
Rating by Do Kim at BMO Capital Markets
11/21/2016BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $46.00N/A
i
Rating by Do Kim at BMO Capital Markets
11/11/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
11/7/2016BMO Capital MarketsReiterated RatingOutperform$40.00N/A
i
Rating by Do Kim at BMO Capital Markets
11/4/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
9/9/2016JMP SecuritiesReiterated RatingOutperform$28.00N/A
i
Rating by Liisa Bayko at JMP Securities
9/8/2016BMO Capital MarketsReiterated RatingOutperform$28.00 ➝ $40.00N/A
i
Rating by Do Kim at BMO Capital Markets
9/7/2016SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $32.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
8/8/2016BMO Capital MarketsReiterated RatingOutperform$25.00 ➝ $28.00N/A
i
Rating by Do Kim at BMO Capital Markets
7/15/2016BMO Capital MarketsReiterated RatingOutperform$25.00N/A
i
Rating by Do Kim at BMO Capital Markets
7/9/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
6/27/2016SVB LeerinkReiterated RatingBuy$27.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/21/2016SVB LeerinkReiterated RatingBuy$4.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/20/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Do Kim at BMO Capital Markets
5/11/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/4/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Do Kim at BMO Capital Markets
4/16/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$25.00N/A
i
3/17/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
3/9/2016SVB LeerinkReiterated RatingOutperform$27.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
(Data available from 3/4/2016 forward)
Travere Therapeutics logo
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $27.40
$27.39
$29.97

50 Day Range

MA: $26.56
$24.25
$28.18

52 Week Range

Now: $27.40
$8.98
$24.96

Volume

786,728 shs

Average Volume

412,277 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, BTIG Research, Canaccord Genuity, TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RTRX.

What is the current price target for Travere Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. Their average twelve-month price target is $28.00, suggesting a possible upside of 2.2%. BMO Capital Markets has the highest price target set, predicting RTRX will reach $33.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $21.00 for Travere Therapeutics in the next year.
View the latest price targets for RTRX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RTRX will outperform the market and that investors should add to their positions of Travere Therapeutics.
View the latest ratings for RTRX.

What other companies compete with Travere Therapeutics?

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected] The official website for Travere Therapeutics is www.retrophin.com.